LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Depreciation and Amortization

Last Annual Value

321.00K

3-Year CAGR

443%

5-Year CAGR

176%

10-Year CAGR

66%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Depreciation and Amortization

LBRX · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
321.00K
331.3%N/AN/A 
1.13M
-4.5%6.3%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
2.17M
0.3%-8.7%N/A
5.28M
-4.5%0.9%15.9%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
5.33M
-11.6%-8.4%N/A
1.80M
1.8%25.1%N/A
11.54M
-17.1%-3.3%N/A
3.50M
12.7%15.4%N/A
8.85M
0.6%24.5%N/A
11.03M
15.8%15.5%51.9%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
3.79M
1.5%18.9%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95